新型抗巨细胞病毒药乐特莫韦的药理作用及临床研究  

Pharmacological effects and clinical trials of a novel anti-CMV drug letermovir

作　　者：张舒 陈晴[1,2] 封宇飞[1] 刘蕾[1] ZHANG Shu1,2 , CHEN Qing1,2 , FENG Yu-fei1 , LIU Lei1(1. Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, Beijing 100730, China; 2. Department of Pharmacy Administration ＆ Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing 100191, China)

机构地区：[1]北京医院药学部国家老年医学中心药物临床风险与个体化应用评价北京市重点实验室,北京100730 [2]北京大学药学院药事管理与临床药学系,北京100191

出　　处：《临床药物治疗杂志》2018年第9期5-8,13,共5页Clinical Medication Journal

摘　　要：乐特莫韦(letermovir)是一种具有新型作用机制的抗巨细胞病毒药物,能抑制病毒末端酶亚基pUL56,防止病毒DNA多联体的分裂和成熟病毒体的形成,对巨细胞病毒具有高度特异性。临床研究表明,乐特莫韦无与给药有关的造血系统或肾脏毒性。本文对乐特莫韦的药理作用、药动学、临床评价以及安全性等内容进行了综述。Letermovir is an anti-CMV drug with a novel mechanism of action. It inhibits the viral terminase subunit pUL56, a component of the terminase complex involved in process of DNA cleavage and packaging. It is highly specific against human CMV. Laboratory evaluation revealed no indication of either hematopoietic or renal toxicity associated with letenrovir administration. This article reviews the pharmacology, pharmacokinetics, clinical evaluation, and safety of letertrmovir.

关 键 词：乐特莫韦 巨细胞病毒 异基因造血干细胞移植 预防 

分 类 号：R987.7[医药卫生—药品]